Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.52 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.52 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.52 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.52 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1626565 | 0.85 | KMT2A (0.57) | KMT2ALMNAMAPTSMN1; SMN2HTT | |
| SCHEMBL1627016 | 0.84 | LMNA (0.56) | KMT2ALMNAMAPTSMN1; SMN2HTT | |
| SCHEMBL1626319 | 0.83 | KMT2A (0.61) | KMT2ALMNAMAPTSMN1; SMN2HTT | |
| SCHEMBL1625587 | 0.83 | KMT2A (0.61) | KMT2ALMNAMAPTSMN1; SMN2HTT | |
| SCHEMBL1626173 | 0.83 | KMT2A (0.61) | KMT2ALMNAMAPTSMN1; SMN2HTT | |
| SCHEMBL1625757 | 0.82 | KMT2A (0.64) | KMT2ALMNAMAPTSMN1; SMN2HTT | |
| SCHEMBL121987 | 0.82 | LMNA (0.61) | KMT2ALMNAMAPTSMN1; SMN2HTT | |
| SCHEMBL11341363 | 0.82 | HCAR3 (0.79) | KMT2ALMNAMAPTSMN1; SMN2HTT | |
| SCHEMBL1624580 | 0.81 | L3MBTL1 (0.64) | KMT2ALMNAMAPTSMN1; SMN2HTT | |
| SCHEMBL1625390 | 0.81 | ALDH3A1 (0.52) | KMT2ALMNAMAPTSMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928119-B2 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PFIZER INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-7479564-B2 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | RAQUALIA PHARMA INC. (JP) | 2009-01-20 | — | — | US | disclosed |
| US-20070155732-A1 | Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents | PFIZER INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070066618-A1 | Use of EP4 Receptor Ligands in the Treatment of IL-6 Involved Diseases | PFIZER INC. | 2007-03-22 | — | — | US | disclosed |
| US-7148234-B2 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PFIZER INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-7141580-B2 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PFIZER INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1666480-A1 | Aryl or Heteroaryl Fused Imidazole Compounds as intermediates for Anti-Inflammatory And Analgesic Agents. | PFIZER PHARMACEUTICALS INC. (JP) | 2006-06-07 | — | — | EP | disclosed |
| EP-1326864-B1 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMA (JP) | 2006-03-15 | — | — | EP | disclosed |
| EP-1499305-A2 | USE OF EP4 RECEPTOR LIGANDS IN THE TREATMENT OF IL-6 INVOLVED DISEASES | Pfizer Japan Inc. (JP) | 2005-01-26 | — | — | EP | disclosed |
| US-20040181059-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2004-09-16 | — | — | US | disclosed |
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | SHIMOJO MASATO | 2003-12-25 | — | — | US | disclosed |
| WO-2003086371-A2 | USE OF EP4 RECEPTOR LIGANDS IN THE TREATMENT OF IL-6 INVOLVED DISEASES | PFIZER JAPAN INC. (JP) | 2003-10-23 | — | — | WO | disclosed |
| EP-1326864-A2 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 2003-07-16 | — | — | EP | disclosed |
| EP-1326606-A2 | EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS | PFIZER PHARMACEUTICALS INC. (JP) | 2003-07-16 | — | — | EP | disclosed |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PFIZER PHARMACEUTICALS INC. (JP) | 2002-06-20 | — | — | US | disclosed |
| WO-2002032422-A2 | EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | disclosed |
| WO-2002032900-A2 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, OPRM1 | KMT2A 2917/4885LMNA 3018/4885MAPT 3250/4885 |
| US-20070066618-A1 | Use of EP4 Receptor Ligands in the Treatment of IL-6 Involved Diseases | PTGER4, PTGER1, IL6 | KMT2A 4355/4885LMNA 3215/4885MAPT 4402/4885 |
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PTGER4, PTGER1, IL6 | KMT2A 4355/4885LMNA 3215/4885MAPT 4402/4885 |
| US-20040181059-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, OPRM1 | KMT2A 2967/4885LMNA 2960/4885MAPT 3288/4885 |
| US-20070155732-A1 | Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents | PTGS1, PTGS2, PTGES | KMT2A 3274/4885LMNA 3084/4885MAPT 3806/4885 |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PTGER4, PTGER1, PTGER2 | KMT2A 3764/4885LMNA 4518/4885MAPT 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.